Catherine Angell Sohn's most recent trade in Maze Therapeutics Inc. was a trade of 26,920 Common Stock done at an average price of $39.1 . Disclosure was reported to the exchange on Jan. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Sale of securities on an exchange or to another person at price $ 39.11 per share. | 06 Jan 2026 | 26,920 | 0 | - | 39.1 | 1,052,785 | Common Stock |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 06 Jan 2026 | 20,744 | 20,744 | - | 10.4 | 216,152 | Common Stock |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 20,744 | 0 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 06 Jan 2026 | 3,281 | 26,920 | - | 10.4 | 34,188 | Common Stock |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 3,281 | 5,805 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 06 Jan 2026 | 2,895 | 23,639 | - | 10.4 | 30,166 | Common Stock |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 2,895 | 316 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 06 Jan 2026 | 2,493 | 2,493 | - | 10.4 | 25,977 | Common Stock |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Sale of securities on an exchange or to another person at price $ 38.62 per share. | 06 Jan 2026 | 2,493 | 0 | - | 38.6 | 96,270 | Common Stock |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 2,493 | 3,211 | - | - | Stock Option (Right to Buy) | |
| Altimmune Inc | Catherine Angell Sohn | Director | Purchase of securities on an exchange or from another person at price $ 4.24 per share. | 05 Jan 2026 | 500 | 1,500 (0%) | 0% | 4.2 | 2,118 | Common Stock, par value $0.0001 |
| Altimmune Inc | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2025 | 48,800 | 48,800 | - | - | Stock Options (option to buy) | |
| Maze Therapeutics Inc | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2025 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Altimmune Inc | Catherine Angell Sohn | Director | Purchase of securities on an exchange or from another person at price $ 5.78 per share. | 17 Mar 2025 | 1,000 | 1,000 (0%) | 0% | 5.8 | 5,785 | Common Stock, par value $0.0001 |
| Altimmune Inc | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 18,600 | 18,600 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Angell Sohn Catherine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Jazz Pharma PLC | Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2023 | 3,075 | 16,109 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharma PLC | Catherine Angell Sohn | Director | Sale of securities on an exchange or to another person at price $ 138.16 per share. | 11 Aug 2023 | 1,241 | 14,868 (0%) | 0% | 138.2 | 171,455 | Ordinary Shares |